Form 8-K - Current report:
SEC Accession No. 0001641172-25-000681
Filing Date
2025-03-26
Accepted
2025-03-26 07:30:13
Documents
15
Period of Report
2025-03-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37037
2 ex3-1.htm EX-3.1 8812
3 ex3-2.htm EX-3.2 135988
  Complete submission text file 0001641172-25-000681.txt   384940

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE erna-20250326.xsd EX-101.SCH 3015
5 XBRL LABEL FILE erna-20250326_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE erna-20250326_pre.xml EX-101.PRE 24165
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3818
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 25770180
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)